Johnson & Johnson reported stronger-than-expected third-quarter earnings for 2024, driven by robust sales of oncology drugs, particularly Darzalex. The company posted an adjusted EPS of $2.42, surpassing the estimated $2.19, and revenue of $22.5 billion, exceeding the forecasted $22.17 billion. This represents a 5.2% year-over-year sales growth. Medicine revenue was $14.58 billion, while MedTech sales reached $7.89 billion. Despite a 9.0% year-over-year decline in adjusted EPS and a 37.5% drop in net income to $2.69 billion, the company raised its full-year operational sales guidance to $89.4 billion to $89.8 billion. Johnson & Johnson also adjusted its full-year adjusted EPS forecast to a range of $9.88 to $9.98, down from the previous range of $9.97 to $10.07, to account for a medical device acquisition.